| # | ํ๊ฒ | ๋ฆฌ๊ฐ๋ | ์ ํ | ์์ง | ์ ์ | ์ ๋ขฐ๋ |
|---|---|---|---|---|---|---|
| 1 | EGFR | cetuximab | ํญ์ฒด ์ธํฐํ์ด์ค | Biopython | 25 contacts, ~200 ร ยฒ | EXPERIMENTAL |
| 2 | EGFR | erlotinib | ์๋ถ์ ๋ํน | Boltz-2 | confidence 0.788, iptm 0.981 | HIGH |
| 3 | PD-1 | pembrolizumab | ํญ์ฒด ์ธํฐํ์ด์ค | Biopython | 52 contacts, ~340 ร ยฒ | EXPERIMENTAL |
| 4 | PD-1 | nivolumab | ํญ์ฒด ์ธํฐํ์ด์ค | Biopython | 32 contacts, ~220 ร ยฒ | EXPERIMENTAL |
| 5 | EGFR | erlotinib | ์๋ถ์ ๋ํน | Vina | -7.605 kcal/mol | MEDIUM |
| 6 | HPV E6 | p53 | ๋ณตํฉ์ฒด ์์ธก | Boltz-2 | confidence 0.366 | EXPLORATORY |
| 7 | HPV E7 | Rb | ๋ณตํฉ์ฒด ์์ธก | Boltz-2 | confidence 0.395 | EXPLORATORY |
| 8 | PI3Kฮฑ | alpelisib | ์๋ถ์ ๋ํน | Boltz-2 | confidence 0.311 | EXPLORATORY |
| 9 | mTOR | everolimus | ์๋ถ์ ๋ํน | โ | โ | ๋๊ธฐ ์ค |
| 10 | PD-L1 | atezolizumab | ํญ์ฒด ๋ณตํฉ์ฒด | Boltz-2 | ๋ณตํฉ์ฒด ์์ธก ์๋ฃ | MEDIUM |
| 11 | EGFR | nimotuzumab | ํญ์ฒด ๋ณตํฉ์ฒด | Boltz-2 | ๋ณตํฉ์ฒด ์์ธก ์๋ฃ | MEDIUM |
| 12 | KRT6A | โ | ๊ตฌ์กฐ ์์ธก | Boltz-2 | ํญPD-1 ๋ด์ฑ ๋ฐ์ด์ค๋ง์ปค | MEDIUM |
| 13 | PD-L1 | โ | ๊ตฌ์กฐ ์์ธก | Boltz-2 | ๊ตฌ์กฐ ์์ธก ์๋ฃ | MEDIUM |
| 14 | WBP5 | pazopanib | ์๋ถ์ ๋ํน | Boltz-2 | confidence 0.499, iptm 0.478 | EXPLORATORY |
| ๋ถ์ผ | ๋ ผ๋ฌธ ์ | ์ฃผ์ ํค์๋ |
|---|---|---|
| ์๊ณผ | ~900 | trifocal IOL, glaucoma, cataract, MIGS, OCT |
| ๋๊ฒฝ๋ถ (HNSCC) | ~1,500 | cetuximab, pembrolizumab, HPV, EGFR, PD-L1 |
| ํฉํ์ด๋/์ฅ์ | ~2,200 | BPC-157, SS-31, MOTS-c, semaglutide, NAD+ |
| PubMed MeSH Baseline | ~15,000+ | MeSH ํํฐ๋ง (60๊ฐ MeSH term) |
| ์์ง | ์ฉ๋ | ์คํ | ๋น์ฉ |
|---|---|---|---|
| Boltz-2 | AI ๊ตฌ์กฐ ์์ธก + ๊ฒฐํฉ | Modal GPU (ํด๋ผ์ฐ๋) | ~$0.02/๊ฑด |
| AutoDock Vina | ์ ํต physics-based ๋ํน | ๋ก์ปฌ (Ryan-home) | ๋ฌด๋ฃ |
| Biopython | ์ธํฐํ์ด์ค ๋ถ์ | ๋ก์ปฌ | ๋ฌด๋ฃ |